Other News

HeartSciences to Present at the LD Micro Invitational XIV Conference

Coronary/Structural Heart by Comments are Disabled

Southlake, TX, April 02, 2024 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences  (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today announced that Chief Executive Officer Andrew Simpson is scheduled to present at the LD Micro Invitational XIV Conference on Tuesday April 9, 2024 at 5:00pm ET at the Sofitel New York. Mr. Simpson will also be hosting one-on-one meetings through the conference.

Continue Reading →

AngioDynamics Announces Settlement of All Patent Litigation with C.R. Bard, Inc.

Financial by 0 comments

LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it has entered into a settlement agreement with Becton, Dickinson and Company (“BD”) […]

Continue Reading →

LifeTech Scientific Corporation Announced 2023 Annual Results: International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid Development

Financial by Comments are Disabled

SHENZHEN, China, April 2, 2024 /PRNewswire/ — LifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its…

Continue Reading →

Innovating “Treadmill Exercise Test AI-Assisted Interpretation System,” CMUH(Taiwan) Timely Saves More Patients with Severe Myocardial Infarction

Coronary/Structural Heart by Comments are Disabled

TAICHUNG, Taiwan, April 2, 2024 /PRNewswire/ — The treadmill exercise test (TET) is an important tool for diagnosing coronary artery disease (CAD), but limited by time spent for the manual interpretation of a dozen charts and the challenges in identifying minor deviations. Traditionally,…

Continue Reading →

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Coronary/Structural Heart by Comments are Disabled

TORONTO, April 02, 2024 (GLOBE NEWSWIRE) — Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Continue Reading →

Haemonetics Corporation Completes Acquisition of Attune Medical

Financial by 0 comments

BOSTON, April 1, 2024 /PRNewswire/ — Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, has completed its previously announced acquisition of privately-held Chicago-based Attune Medical, the manufacturer of the ensoETM® proactive esophageal cooling device. EnsoETM is the only FDA-cleared temperature regulation device indicated for esophageal protection […]

Continue Reading →
1 … 301 302 303 304 305 … 1,358